Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $52 from $49 and keeps a Buy rating on the shares after the FDA approved Vizz a week earlier than the action date. The firm says Lenz has a week “head-start” to start commercialization of the drug.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop
- Lenz Therapeutics announces FDA approval of Vizz eye drop
- LENZ Therapeutics trading resumes
- LENZ Therapeutics trading halted, news pending
- LENZ Therapeutics’ LNZ100 Eye Drop Gains Buy Rating Amid Positive KOL Feedback and Strategic Market Positioning